Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Fresenius SE & Co. KGaA
  6. News
  7. Summary
    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report
Delayed Xetra  -  11:35 2022-08-17 am EDT
24.24 EUR   -2.69%
08/15Moody's Keeps Fresenius' Rating Unchanged Despite Operating Headwinds
MT
08/15Moody's Confirms Fresenius Medical Care's Stable Outlook Amid Muted Operating Performance
MT
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S.
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FRESENIUS SE : Credit Suisse reaffirms its Neutral rating

08/05/2022 | 02:53pm EDT
share with twitter
share with LinkedIn
share with facebook

Analyst Christoph Gretler from Credit Suisse research gives the stock a Neutral rating. The target price is lowered from EUR 38 to EUR 30.


© MarketScreener with dpa-AFX Analyser 2022
All news about FRESENIUS SE & CO. KGAA
08/15Moody's Keeps Fresenius' Rating Unchanged Despite Operating Headwinds
MT
08/15Moody's Confirms Fresenius Medical Care's Stable Outlook Amid Muted Operating Performan..
MT
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08FRESENIUS : Kabi introduces 2D barcodes in the US
PU
08/05FRESENIUS SE : Credit Suisse reaffirms its Neutral rating
MD
08/05FRESENIUS SE : Barclays maintains a Buy rating
MD
08/05FRESENIUS SE : Warburg Research remains its Buy rating
MD
08/05FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by persons
EQ
08/05FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by persons
EQ
08/05FRESENIUS SE : Deutsche Bank reiterates its Neutral rating
MD
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Financials
Sales 2022 40 357 M 41 042 M 41 042 M
Net income 2022 1 744 M 1 774 M 1 774 M
Net Debt 2022 21 581 M 21 947 M 21 947 M
P/E ratio 2022 7,87x
Yield 2022 3,57%
Capitalization 13 653 M 13 885 M 13 885 M
EV / Sales 2022 0,87x
EV / Sales 2023 0,81x
Nbr of Employees 318 647
Free-Float 73,0%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 24,24 €
Average target price 39,48 €
Spread / Average Target 62,9%
EPS Revisions
Managers and Directors
Stephan Sturm Chairman-Management Board & CEO
Rachel Clare Empey Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Michael Albrecht Independent Member-Supervisory Board
Konrad Kölbl Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
FRESENIUS SE & CO. KGAA-31.53%14 277
AIER EYE HOSPITAL GROUP CO., LTD.-10.40%30 007
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY31.85%19 913
IHH HEALTHCARE-11.44%12 797
BANGKOK DUSIT MEDICAL SERVICES20.65%12 664
RAMSAY HEALTH CARE LIMITED2.07%11 658